KinDex Pharmaceuticals

About:

KinDex Pharmaceuticals is a developer of novel therapeutics used to help patients suffering from metabolic disorders.

Website: http://kindexpharmaceuticals.com/

Top Investors: Polaris Partners, Jeff Katke, Jeffrey Bland

Description:

KinDex Pharmaceuticals is a developer of novel therapeutics used to help patients suffering from metabolic disorders. It was established to focus on the discovery and development of molecules that improve women’s health and impact chronic disease. KinDex Pharmaceuticals is developing therapeutics that work through the Bitter Taste Receptors (TAS2Rs), a family of GPCR receptors that target inflammation and metabolic dysfunction.

Total Funding Amount:

$5.83M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Seattle, Washington, United States

Founded Date:

2009-01-01

Contact Email:

neilegrayson(AT)kindextherapeutics.com

Founders:

Jeffrey Bland

Number of Employees:

1-10

Last Funding Date:

2016-08-30

IPO Status:

Private

Industries: